ReviewCell death discovery2025
Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications.
Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- EGFL6 predicts unfavorable prognosis and serves as a potential indicator in esophageal carcinoma.Discover oncology · 2026Article
- Identification of serum 5'tRF-Val as a promising non-invasive biomarker for early detection of esophageal cancer.Scientific reports · 2026Article
- EpCAM as a novel target of MARCH8: implications for esophageal squamous cell carcinoma progression.Journal of molecular histology · 2026Article
- The critical role of ferroptosis in thyroid cancer development and potential therapeutic implications.Frontiers in oncology · 2026Review
- From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson's disease.Frontiers in immunology · 2025Review
- Redefining cell death: ferroptosis as a game-changer in ophthalmology.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of medical and health care, esophageal cancer (EC) has become a disease of concern to the scientific research community. At present, among all treatment regimens for EC, surgical resection is conducive to the prognosis of early patients neoadjuvant therapies are recommended for advanced patients. However, treatments now are not satisfactory in suppressing the progression of EC. Ferroptosis is one distinctive cell death mode, noted for the accumulation of iron as well as lipotoxicity, which induce cell membrane to breakdown. As a star protein of ferroptosis related pathway, GPX4 is related to the homeostatic imbalance of tumor immune microenvironment (TIME) of EC, thereby regulating the onset as well as progression of the cancer. In our manuscript, we present the mechanisms involved in ferroptosis, the functions of ferroptosis in the TIME. We also focused on the progression about ferroptosis in EC, as well as targeting ferroptosis-related pathways to delay the development of EC. We expect that these contents can expand fresh insights and aim for EC therapeutic strategy in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.